Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with
cognition. Currently, there are no FDA-approved treatments targeting cognitive function in
Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used
in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as
compared to treatment with a placebo pill in combination with standard anti-inflammatory
drugs in women with MS.
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Recruiting
University of California, Los Angeles
Phase 2
2011-10-01
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with
cognition. Currently, there are no FDA-approved treatments targeting cognitive function in
Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used
in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as
compared to treatment with a placebo pill in combination with standard anti-inflammatory
drugs in women with MS.
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
Completed
University of Colorado, Denver
Phase 3
2017-01-01
This is a prospective between and within group observational study to determine differences
in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS)
patients who have been administered at least two infusions of rituximab, six months apart and
are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on
rituximab as a comparison cohort from the clinic population treated as part of clinical care.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
